BGB-A317

DRUG5 trials

Conditions

Adenoid Cystic CarcinomaAdvanced CancerAdvanced Solid TumorsAnti-PD-1Colorectal CancerGastric CancerNeoadjuvant ChemotherapyNeoadjuvant Immunotherapy

Phase 1

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

CompletedNCT02407990

BeiGeneAdvanced Cancer

Start: 2015-06-02End: 2020-08-12Updated: 2021-11-17

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

CompletedNCT03287427

Peter MacCallum Cancer Centre, AustraliaAdenoid Cystic Carcinoma, Colorectal Cancer

Start: 2018-08-22End: 2022-12-14Updated: 2023-02-15

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

TerminatedNCT03379259

BeiGeneAdvanced Solid Tumors

Start: 2017-11-27End: 2020-09-08Updated: 2024-10-26

Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)

CompletedNCT04963088

The First Affiliated Hospital with Nanjing Medical UniversityGastric Cancer

Start: 2021-03-06End: 2024-03-20Updated: 2025-06-26

Phase 2

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

NCT04815408

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAnti-PD-1, Neoadjuvant Chemotherapy, Neoadjuvant Immunotherapy +1

Start: 2021-04-01End: 2025-04-01Target: 40Updated: 2021-03-25

Signal Transduction and Targeted Therapy2026-07-03

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

BMJ Open2025-02-011 citations

Alternative dosing regimens of tislelizumab proposed using modeling and simulation.

Journal of Clinical Oncology2025-01-27

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)

Frontiers in Immunology2023-10-316 citations

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial

Frontiers in Oncology2023-04-1712 citations

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.

2023-03-078 citations

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

British Journal of Cancer2023-02-1613 citations

Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

Journal of Clinical Oncology2023-01-243 citations

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.

2022-07-0210 citations

Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab

Cancer Research2022-06-15

Abstract LB514: CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types

Cancer Research2022-06-15

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

JAMA Oncology2021-04-01380 citations

77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Regular and Young Investigator Award Abstracts2020-11-014 citations

79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)

Regular and Young Investigator Award Abstracts2020-11-012 citations

76 Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab

Regular and Young Investigator Award Abstracts2020-11-012 citations

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Cancer Science2020-10-13112 citations

Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors

Cancer Research2020-08-151 citations

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Journal for ImmunoTherapy of Cancer2020-06-01145 citations

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology2020-05-203 citations

Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-20

16 more papers not shown

BGB-A317

Sponsors

Conditions

Phase 1

Phase 2

Related Papers